文献速递免疫规划

印尼婴幼儿和儿童接种三价流感血凝素疫苗的免疫原性与安全性

Immunogenicity and safety of a Trivalent Influenza HA vaccine in Indonesian infants and children.
PubMed 文献 · Vaccine · 2018-03-16

本研究为在印尼雅加达东部开展的II期开放标签临床试验,纳入405名6月龄至11岁健康儿童,接种1或2剂Flubio®三价流感血凝素疫苗(间隔28天)。接种后所有受试者对所有疫苗株均达到血清保护(血凝抑制抗体滴度≥1:40)且血清转化率升高,几何平均滴度显著增加;多数不良反应为轻度,未报告与疫苗相关的严重不良事件。

要点

  • 6月龄至11岁儿童接种1或2剂Flubio®疫苗后,所有疫苗株血凝抑制抗体滴度均≥1:40。
  • 接种后几何平均滴度显著增加,所有受试者均达到血清保护和血清转化率升高。
  • 多数不良反应为轻度,未报告与疫苗相关的严重不良事件。

核心结论

  • Flubio®(三价流感血凝素疫苗)对6月龄至11岁儿童具有免疫原性且安全性良好。

研究设计与样本

  • II期、开放标签临床试验,在印尼雅加达东部于2014年5月至7月开展,纳入405名6月龄至11岁健康儿童,分为A组(6-35月龄)、B组(3-8岁)、C组(9-11岁),接种1或2剂Flubio®疫苗,间隔28天。
  • Flubio®疫苗包含A/California/7/2009(H1N1)pandemic 09、A/Texas/50/2012(H3N2)和B/Massachusetts/2/2012株。
  • 抗体滴度在第1次访视(第0天)、第2次访视(首剂后28天/+7天)和第3次访视(第2剂后28天/+7天)检测;安全性随访至每剂接种后28天。

主要发现

  • 404名受试者完成研究;接种后所有受试者对所有疫苗株均达到血清保护,血凝抑制抗体滴度≥1:40。
  • 接种后所有受试者血清转化率升高,几何平均滴度显著增加。
  • 接种后30分钟内,14.6%受试者出现局部反应,2%出现全身反应;接种后30分钟至72小时,35.1%受试者出现局部反应,13.6%出现全身反应。
  • 多数反应为轻度,未报告与疫苗相关的严重不良事件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: High rate of influenza infection in children made influenza vaccination strongly recommended for all person aged >6 months in Indonesia. Bio Farma Trivalent Influenza HA (Flubio®) vaccine has been used in adolescents and adults, resulted in increased seroconversion, seroprotection rates and geometric mean titer (GMT). However, no data is available regarding its efficacy and safety in children. This study aimed to assess the immunogenicity and safety of Flubio® vaccine in infants and children. MATERIALS AND METHODS: This was a phase II, open-labeled, clinical trial conducted on healthy children aged 6 month-11 years, vaccinated with 1 or 2 doses of Influenza HA vaccine, with a 28-day interval. Flubio® vaccine composed of A/California/7/2009 (H1N1) pandemic 09, A/Texas/50/2012 (H3N2), and B/Massachusetts/2/2012 strain. This study was held at East Jakarta, Indonesia from May until July 2014. A Total of 405 subjects were included and divided into three groups: A(6-35 months), B(3-8 years), and C(9-11 years). Antibody titer was measured at visit V1 (Day 0), V2 (28 days/+7days after the first dose) and V3 (28 days/+7days after second dose). The seroprotection and seroconversion rates were assessed. Safety was assessed up to 28 days following each dose. RESULTS: A total of 404 subjects completed the study. After vaccination, all subjects achieved seroprotection and increased seroconversion rates, with post-vaccination antibody titer of ≥1:40 HI for all strains. The GMT also increased significantly. Within 30 min after vaccination, 14.6% and 2% had local and systemic reactions; meanwhile, between 30 min to 72 h after vaccination, 35.1% and 13.6% subjects had local and systemic reactions, respectively. Most reactions were mild. No serious adverse event (SAE) was reported related to vaccine. CONCLUSION: Flubio® (Influenza HA Trivalent) vaccine is immunogenic and safe for children aged 6 months-11 years. TRIAL REGISTRATION: The trial is registered at the US National Institutes of Health (ClinicalTrials.gov) #NCT02093260.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Soedjatmiko S, Medise BE, Gunardi H, et al. Immunogenicity and safety of a Trivalent Influenza HA vaccine in Indonesian infants and children. Vaccine. 2018. PMID: 29551225. doi:10.1016/j.vaccine.2018.02.114

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。